Vaxart, Inc. (NASDAQ:VXRT) has a beta value of 0.06 and has seen 204,000,000 shares traded in the last trading session. The company, currently valued at $901.87 Million, closed the last trade at $7.78 per share which meant it gained $2.48 on the day or 46.79% during that session. The VXRT stock price is -124.81% off its 52-week high price of $17.49 and 96.79% above the 52-week low of $0.25. If we look at the company’s 10-day average daily trading volume, we find that it stood at 14.38 Million shares traded. The 3-month trading volume is 28.66 Million shares.

The consensus among analysts is that Vaxart, Inc. (VXRT) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 3 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.09.

Vaxart, Inc. (NASDAQ:VXRT) trade information

Wall Street analysts have a consensus price target for the stock at $19.67, which means that the shares’ value could jump 152.83% from current levels. The projected low price target is $17 while the price target rests at a high of $22. In that case, then, we find that the current price level is +182.78% off the targeted high while a plunge would see the stock lose 118.51% from current levels.

Vaxart, Inc. (VXRT) estimates and forecasts

Figures show that Vaxart, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +559.32% over the past 6 months, with this year growth rate of -59.3%, compared to 16% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 71.9% and 30.8% for the next quarter. Revenue growth from the last financial year stood is estimated to be -24.9%.

3 analysts offering their estimates for the company have set an average revenue estimate of $1.17 Million for the current quarter. 3 have an estimated revenue figure of $2.9 Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $440Million and $3.92 Million respectively for this quarter and the next, and analysts expect sales will grow by 165.9% for the current quarter and -25.9% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +32% over the past 5 years. Earnings growth for 2020 is a modest +70.2%.

Vaxart, Inc. (NASDAQ:VXRT)’s Major holders

Insiders own 1.21% of the company shares, while shares held by institutions stand at 36.23% with a share float percentage of 36.68%. Investors are also buoyed by the number of investors in a company, with Vaxart, Inc. having a total of 36 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 3.37 Million shares worth more than $29.79 Million. As of June 29, 2020, Blackrock Inc. held 3.08% of shares outstanding.

The other major institutional holder is Citadel Advisors LLC, with the holding of over 3.1 Million shares as of June 29, 2020. The firm’s total holdings are worth over $27.41 Million and represent 2.84% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are iShares Russell 2000 ETF and Vanguard Extended Market Index Fund. As of June 29, 2020, the former fund manager holds about 0.84% shares in the company for having 917617 shares of worth $8.12 Million while later fund manager owns 618.03 Thousand shares of worth $5.47 Million as of June 29, 2020, which makes it owner of about 0.57% of company’s outstanding stock.